(Q40169126)

English

The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.

scientific article published on 19 February 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Erb-b2 receptor tyrosine kinase 2

1 reference

based on heuristic

inferred from title

10

object named as

Weir BA

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

author name string

Minami Y

1

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Shimamura T

2

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Shah K

3

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

LaFramboise T

4

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Glatt KA

5

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Liniker E

6

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Borgman CL

7

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Haringsma HJ

8

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Feng W

9

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Lowell AM

11

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Lee JC

12

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Wolf J

13

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Shapiro GI

14

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Wong KK

15

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Meyerson M

16

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Thomas RK

17

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

language of work or name

0 references

publication date

19 February 2007

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

34

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

5023-5027

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

https://scigraph.springernature.com/pub.10.1038/sj.onc.1210292

0 references

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210292

7 January 2021

based on heuristic

inferred from DOI database lookup

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210292

7 January 2021

based on heuristic

inferred from DOI database lookup

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210292

7 January 2021

based on heuristic

inferred from DOI database lookup

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210292

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210292

7 January 2021

based on heuristic

inferred from DOI database lookup

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210292

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210292

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210292

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210292

7 January 2021

based on heuristic

inferred from DOI database lookup

An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210292

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210292

7 January 2021

based on heuristic

inferred from DOI database lookup

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210292

7 January 2021

based on heuristic

inferred from DOI database lookup

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210292

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210292

7 January 2021

based on heuristic

inferred from DOI database lookup

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210292

7 January 2021

based on heuristic

inferred from DOI database lookup

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210292

7 January 2021

based on heuristic

inferred from DOI database lookup

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210292

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumor activity of HER-2 inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210292

7 January 2021

based on heuristic

inferred from DOI database lookup

A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210292

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210292

7 January 2021

based on heuristic

inferred from DOI database lookup

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210292

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210292

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210292

7 January 2021

based on heuristic

inferred from DOI database lookup

Lung cancer: intragenic ERBB2 kinase mutations in tumours

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210292

7 January 2021

based on heuristic

inferred from DOI database lookup

Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210292

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.ONC.1210292

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40169126&oldid=1498135437"